6533b82afe1ef96bd128b8ce
RESEARCH PRODUCT
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
Victor Mangas-sanjuanVictor Mangas-sanjuanFrancisco J. Otero-espinarLaura García-quintanillaAnxo Fernández-ferreiroAnxo Fernández-ferreiroPablo AguiarMiguel González-barciaOlalla MaroñasAndrea Luaces-rodríguezAndrea Luaces-rodríguezCristina Mondelo-garcíaMaría Gil-martínezIrene Zarra-ferrosubject
intravitrealgenetic structuresBevacizumabmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceVitrectomyReviewvascular endothelial growth factor/antagonists &bevacizumabPharmacologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsRanibizumabinhibitorsVascular endothelial growth factor/antagonists & inhibitorsMedicineDistribution (pharmacology)Pharmacokineticsranibizumab030304 developmental biologyAflibercept0303 health sciencesbusiness.industryafliberceptvascular endothelial growth factor/antagonists & inhibitorsIntravitreal administrationMacular degenerationmedicine.diseaseBevacizumabAge-Related Macular Degeneration030221 ophthalmology & optometryRanibizumabbusinessAfliberceptIntravitrealpharmacokineticsmedicine.drugdescription
Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance. This work was partially supported by the ISCIII (PI17/00940, RETICS Oftared, RD16/0008/0003 and RD12/0034/0017) cofunded by FEDER and by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100) SI
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-07-01 |